|Bid||22.99 x 1000|
|Ask||26.50 x 800|
|Day's Range||21.51 - 24.73|
|52 Week Range||21.51 - 56.59|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.75|
ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will participate in a fireside chat at the Cowen 41st Annual Health Care Conference on Thursday, March 4, 2021, at 12:50 p.m. ET.
By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT On January 20th, 2021, Lantern Pharma Inc. (NASDAQ:LTRN) announced that it had closed a public offering with gross proceeds of $69 million, giving the firm ample resources to achieve important clinical milestones. In addition, Lantern has also added an indication in atypical teratoid rhabdoid tumors (ATRT), details for which